Drug Profile
Research programme: anti-MBL monoclonal antibodies - Alexion AstraZeneca Rare Disease
Alternative Names: Anti-MBL mAbs; Anti-MBL monoclonal antibodiesLatest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Brigham and Womens Hospital
- Class Monoclonal antibodies
- Mechanism of Action Cell adhesion molecule inhibitors; Complement C3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Vascular disorders
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 30 Jan 2007 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 30 Jan 2007 Discontinued - Preclinical for Vascular disorders in USA (unspecified route)